Mohammadi-Sartang Mohsen, Mazloom Zohreh, Sohrabi Zahra, Sherafatmanesh Saeed, Barati-Boldaji Reza
Department of Clinical Nutrition, Shiraz University of Medical Sciences, School of Nutrition and Food Sciences, Shiraz, Iran.
Department of Clinical Nutrition, Shiraz University of Medical Sciences, School of Nutrition and Food Sciences, Iran.
Pharmacol Res. 2017 Mar;117:394-405. doi: 10.1016/j.phrs.2017.01.012. Epub 2017 Jan 13.
The results of human clinical trials have revealed that the effects of resveratrol on adipokines are inconsistent. Our objective was to elucidate the role of resveratrol supplementation on adipokines through a systematic review and a meta-analysis of available randomized placebo-controlled trials (RCTs). The search included PubMed-MEDLINE, SCOPUS and ISI web of sciences database till up to 6th November 2016. Weight mean differences (WMD) were calculated for net changes in adipokines using fixed-effects or random-effects models; meta-regression analysis and publication bias were conducted in accordance with standard methods. Nine RCTs with 11 treatment arms were eligible for inclusion in this systematic review and meta-analysis. Meta-analysis of data from 10 treatment arms showed a significant change in plasma adiponectin concentrations following resveratrol supplementation (WMD: 1.10μg/ml, 95%CI: 0.88, 1.33, p<0.001); Q=11.43, I=21.29%, p=0.247). There was a significant greater adiponectin-reducing effect in trials with higher than or equal to 100mg/day (WMD: 1.11μg/ml, 95%CI: 0.88, 1.34, p<0.001), versus those with less than 100 mg/day dosage (WMD: 0.84μg/ml, 95%CI: -0.62, 2.31, p=0.260). Meta-analysis of data from 5 treatment arms did not find any significant change in plasma leptin concentrations following resveratrol supplementation (WMD: 3.77ng/ml, 95% CI: -2.28, 9.83, p=0.222; Q=8.00, I=50.01%). Resveratrol significantly improves adiponectin but does not affect leptin concentrations. Additional studies are required to further evaluate the potential benefits of resveratrol on adipokines in humans.
人体临床试验结果显示，白藜芦醇对脂肪因子的影响并不一致。我们的目标是通过对现有随机安慰剂对照试验（RCT）进行系统评价和荟萃分析，阐明补充白藜芦醇对脂肪因子的作用。检索范围包括截至2016年11月6日的PubMed-MEDLINE、SCOPUS和ISI科学网数据库。使用固定效应或随机效应模型计算脂肪因子净变化的加权平均差（WMD）；按照标准方法进行荟萃回归分析和发表偏倚分析。九项RCT（共11个治疗组）符合纳入本系统评价和荟萃分析的条件。对10个治疗组的数据进行荟萃分析显示，补充白藜芦醇后血浆脂联素浓度有显著变化（WMD：1.10μg/ml，95%CI：0.88，1.33，p<0.001；Q=11.43，I=21.29%，p=0.247）。在每日剂量高于或等于100mg的试验中，脂联素降低效果显著更大（WMD：1.11μg/ml，95%CI：0.88，1.34，p<0.001），而每日剂量低于100mg的试验中（WMD：0.84μg/ml，95%CI：-0.62，2.31，p=0.260）则不然。对5个治疗组的数据进行荟萃分析未发现补充白藜芦醇后血浆瘦素浓度有任何显著变化（WMD：3.77ng/ml，95%CI：-2.28，9.83，p=0.222；Q=8.00，I=50.01%）。白藜芦醇可显著改善脂联素水平，但不影响瘦素浓度。需要进一步研究以评估白藜芦醇对人体脂肪因子的潜在益处。
